Eukaryotic Cell Patents (Class 424/93.21)
-
Patent number: 10865231Abstract: An immunoresponsive cell, such as a T-cell expressing (i) a second generation chimeric antigen receptor comprising: (a) a signalling region; (b) a co-stimulatory signalling region; (c) a transmembrane domain; and (d) a binding element that specifically interacts with a first epitope on a target antigen; and (ii) a chimeric costimulatory receptor comprising (e) a co-stimulatory signalling region which is different to that of (b); (f) a transmembrane domain; and g) a binding element that specifically interacts with a second epitope on a target antigen. This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.Type: GrantFiled: May 18, 2020Date of Patent: December 15, 2020Assignee: King's College LondonInventors: John Maher, Daniela Yordanova Achkova, Lynsey May Whilding, Benjamin Owen Draper
-
Patent number: 10864271Abstract: Disclosed is a method of treating a tumor in a patient, comprising (a) administering riluzole in an amount effective to sensitize the tumor cells to ionizing radiation, and (b) irradiating the tumor cells with ionizing radiation in a dose effective to reduce tumor cell growth. The method can further comprise administering an effective amount of one or more additional therapeutic agents.Type: GrantFiled: February 15, 2013Date of Patent: December 15, 2020Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Atif Jalees Khan, Suzie Chen, James S. Goydos, Bruce G. Haffty
-
Patent number: 10857184Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.Type: GrantFiled: June 6, 2019Date of Patent: December 8, 2020Assignee: CRISPR Therapeutics AGInventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
-
Patent number: 10851359Abstract: The invention provides manipulated adenovirus, i.e. a viral particle based on a manipulated adenovirus, for use as a medicament, especially for use in the treatment of tumours. The viral particle of the invention has the advantage of having a preference or specificity for tumour cells, yielding a preferred infection of tumour cells. The viral particle is based on adenovirus, especially type C, preferably serotype 2 (Ad2), more preferably serotype 5 (Ad5), in which the native entire fiber protein, and its coding sequence, respectively, is deleted and replaced by a fusion protein providing specificity for cell surface bound polysialic acid.Type: GrantFiled: March 24, 2016Date of Patent: December 1, 2020Assignee: Medizinische Hochschule HannoverInventors: Rita Gerardy-Schahn, Florian Kuehnel, Nikolas Martin, David Schwarzer
-
Patent number: 10842820Abstract: Provided herein are kits for processing stem cells from bone marrow or umbilical cord blood, comprising: a) a precipitation reagent comprising an aqueous solution of 0.1-30% hydroxyethyl starch or 0.1-30% methyl cellulose, and 0.1-20% of cerebroprotein hydrolysate; and b) a separation reagent comprising an aqueous solution comprising Ficoll and diatrizoate and having a density of 1.0-1.2 g/ml, and methods of use. Further provided herein is a collection of stem cells obtained by the kits and methods disclosed herein comprising stem cells from bone marrow or umbilical cord blood, and uses thereof.Type: GrantFiled: December 16, 2015Date of Patent: November 24, 2020Assignee: Mingqi TANGInventor: Mingqi Tang
-
Patent number: 10828334Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.Type: GrantFiled: March 11, 2020Date of Patent: November 10, 2020Assignee: Mesoblast International SárlInventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
-
Patent number: 10829767Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.Type: GrantFiled: November 14, 2019Date of Patent: November 10, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventor: James N. Kochenderfer
-
Patent number: 10829769Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.Type: GrantFiled: November 15, 2019Date of Patent: November 10, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventor: James N. Kochenderfer
-
Patent number: 10828352Abstract: The present disclosure provides compositions and methods for boosting, augmenting or enhancing the efficacy of the adoptive cellular immunotherapy by using modified T cells expressing an antigen binding protein in conjunction with modified cells (such as hematopoietic progenitor cells, modified human immune system cells or a combination thereof) expressing the antigen specifically bound by the antigen binding protein of the modified T cells.Type: GrantFiled: October 27, 2015Date of Patent: November 10, 2020Assignee: Fred Hutchinson Cancer Research CenterInventors: Susanna Carolina Berger, Stanley R. Riddell
-
Patent number: 10813955Abstract: The disclosure is directed to the use of nonviable pluripotent stem cells to improve age-related declines in tissue and organ function. In one aspect, nonviable pluripotent stem cells are used to improve cognition in a subject in need thereof. In another aspect, nonviable pluripotent stem cells are used to improve age-related cardiac dysfunction in a subject in need thereof. Administration of nonviable pluripotent stem cells provides a transient and safe form of heterochronic cellular transbiosis.Type: GrantFiled: September 26, 2016Date of Patent: October 27, 2020Assignee: Genani CorporationInventor: Richard K. Burt
-
Patent number: 10813939Abstract: Inhibition of bromodomain proteins in antigen presenting cells is shown herein to be more inflammatory, to display lower expression of the immunosuppressive molecule PDL1, and to be capable of restoring the responsiveness of tolerant T-cells. Therefore, disclosed is a method for promoting T-cell activation during cancer immunotherapy in a subject that involves administering to a subject undergoing cancer immunotherapy a composition comprising a bromodomain inhibitor. Also disclosed is a method for treating cancer in a subject, comprising co-administering to the subject a bromodomain inhibitor and an immunostimulatory agent.Type: GrantFiled: December 4, 2015Date of Patent: October 27, 2020Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Eduardo M. Sotomayor, James Bradner, Jianguo Tao
-
Patent number: 10799536Abstract: Disclosed herein are engineered natural killer cells that have been modified to express chimeric antigen receptors (CARs). The cells optionally contain other modifications that improve tumor specific cytotoxicity and homing to tumor sites. Also contemplated are methods for using the engineered natural killer cells to treat patients with cancer.Type: GrantFiled: December 11, 2017Date of Patent: October 13, 2020Assignee: ONK Therapeutics LimitedInventor: Michael Eamon Peter O'Dwyer
-
Patent number: 10800832Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.Type: GrantFiled: May 3, 2019Date of Patent: October 13, 2020Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Leonie Alten, Dominik Maurer, Sebastian Bunk, Claudia Wagner, Mathias Ferber
-
Patent number: 10792298Abstract: Pharmaceutical compositions are provided which include a microRNA pool capable of promoting, stimulating or increasing neuronal differentiation, as well as methods for treating, ameliorating and/or preventing depression or diseases where damage to nervous tissue occurs, such as neurological diseases, by means of such microRNA pool.Type: GrantFiled: September 18, 2017Date of Patent: October 6, 2020Assignee: FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIAInventors: Davide De Pietri Tonelli, Meritxell Pons Espinal
-
Patent number: 10786537Abstract: The present invention provide for methods of inducing an oncolytic effect on tumor cells using Zika virus. The invention also provides for inducing an oncolytic effect on brain tumors and treating brain tumors, and in particular, glioblastomas and neuroblastoma. The treatment involves the administration of Zika virus, which has an oncolytic effect on the tumor cells.Type: GrantFiled: August 17, 2017Date of Patent: September 29, 2020Assignee: Cedars-Sinai Medical CenterInventors: Vaithilingaraja Arumugaswami, Joshua Breunig
-
Patent number: 10786533Abstract: Provided are engineered cells for adoptive therapy, including NK cells and T cells. Also provided are compositions for engineering and producing the cells, compositions containing the cells, and methods for their administration to subjects. In some embodiments, the cells contain genetically engineered antigen receptors that specifically bind to antigens, such as chimeric antigen receptors (CARs) and costimulatory receptors. In some embodiments, the cells include receptors targeting multiple antigens. In some embodiments, the cells include repression of one or more gene product, for example, by disruption of a gene encoding the gene product. In some embodiments, a gene encoding an antigen recognized by the engineered antigen receptor is disrupted, reducing the likelihood of targeting of the engineered cells. In some embodiments, the antigen recognized by the engineered antigen receptor is related to a tumor antigen recognized by the engineered antigen receptor.Type: GrantFiled: July 15, 2016Date of Patent: September 29, 2020Assignee: Juno Therapeutics, Inc.Inventors: Kendall M. Mohler, Hyam I. Levitsky, Blythe Sather
-
Patent number: 10774124Abstract: The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.Type: GrantFiled: December 9, 2016Date of Patent: September 15, 2020Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Richard T. Lee, Vincent Segers
-
Patent number: 10767184Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.Type: GrantFiled: August 31, 2017Date of Patent: September 8, 2020Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventor: James N. Kochenderfer
-
Patent number: 10766829Abstract: [Problem] The present invention seeks to provide a composition for plants that is highly safe and that contributes to early harvesting, increasing yield, and increasing added value of crops. Specifically, the present invention provides a yeast extract that, by addition to a foliar surface spray or to soil or water, provides an effect of promoting growth, an effect of root lengthening, an effect of improved taste, and an effect of increased amino acid content of a plant. A substance obtained from yeast that is edible and considered to be safe is preferred as the yeast extract. [Means for Solving the Problem] A yeast extract having a peptide content of 5 wt % or more and an RNA content of 5 wt % or more is sprayed onto or provided as fertilizer to a plant. The yeast extract is preferably derived from Candida utilis, which is edible and considered to be safe.Type: GrantFiled: March 16, 2016Date of Patent: September 8, 2020Assignee: KOHJIN LIFE SCIENCES CO., LTD.Inventors: Tomohiro Nakagawa, Yoshie Yasumatsu, Naoto Kaji, Kenichi Ason
-
Patent number: 10759842Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.Type: GrantFiled: May 3, 2019Date of Patent: September 1, 2020Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Leonie Alten, Dominik Maurer, Sebastian Bunk, Claudia Wagner, Mathias Ferber
-
Patent number: 10760046Abstract: The present disclosure provides methods of patterning cells on a surface of a substrate. The methods include disposing a pattern of nucleic acids on a surface of a substrate, and contacting the patterned nucleic acids under hybridization conditions with a first suspension of cells, where cells of the first suspension include cell surface-attached nucleic acids complementary to the patterned nucleic acids, and where the cell surface-attached nucleic acids hybridize to the patterned nucleic acids to pattern the cells on the surface of the substrate. Systems and kits for practicing the methods are also provided.Type: GrantFiled: November 5, 2013Date of Patent: September 1, 2020Assignee: The Regents of the University of CaliforniaInventors: Zev Jordan Gartner, Jennifer S. Liu, Noel Youngho Jee, Michael E. Todhunter
-
Patent number: 10751276Abstract: The present invention relates to a composition comprising ex-vivo expanded adipose tissue derived stem cell (ASC) or ex-vivo expanded adipose tissue-derived stem cells (ASC) mixed with harvested fat tissue at a ratio of 5.0×104-2.0×108ASCs/mL fat; for example 1.0×105-2.0×107 and the use of ex-vivo expanded adipose tissue-derived stem cells or ex-vivo expanded adipose tissue-derived stem cell enriched fat grafts as an agent for cosmetic breast filling/augmentation or for facial filling/reju-venation.Type: GrantFiled: June 26, 2014Date of Patent: August 25, 2020Assignee: STEMFORM APSInventor: Stig-Frederik Trojahn Kølle
-
Patent number: 10752684Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a ROR1 monoclonal antibody, conferring specific immunity against ROR1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as breast, colon, lung, and kidney tumors.Type: GrantFiled: July 29, 2015Date of Patent: August 25, 2020Assignee: CELLECTISInventor: Cècile Schiffer-Mannioui
-
Patent number: 10744158Abstract: The present invention includes vaccine compositions and methods for using these vaccine compositions in active immunotherapy. The vaccine compositions include allogeneic activated Th1 memory cells. The compositions can also include one or more disease-related antigens. The methods include administering the vaccine compositions to provide a Th1 footprint in normal individuals or patients susceptible to disease or having minimal residual disease.Type: GrantFiled: June 22, 2017Date of Patent: August 18, 2020Assignee: MIRROR BIOLOGICS, INC.Inventor: Michael Har-Noy
-
Patent number: 10736919Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.Type: GrantFiled: June 4, 2019Date of Patent: August 11, 2020Assignee: CRISPR Therapeutics AGInventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
-
Patent number: 10738313Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.Type: GrantFiled: November 14, 2019Date of Patent: August 11, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventor: James N. Kochenderfer
-
Patent number: 10738312Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.Type: GrantFiled: November 14, 2019Date of Patent: August 11, 2020Assignee: The United States of America,as represented by the Secretary, Department of Health and Human ServicesInventor: James N. Kochenderfer
-
Patent number: 10736918Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.Type: GrantFiled: November 17, 2017Date of Patent: August 11, 2020Assignees: Fred Hutchinson Cancer Research Center, Seattle Children's HospitalInventors: Michael C. Jensen, Stanley R. Riddell, Michael Hudecek
-
Patent number: 10729725Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.Type: GrantFiled: June 7, 2019Date of Patent: August 4, 2020Assignee: CRISPR Therapeutics AGInventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
-
Patent number: 10729789Abstract: The present application discloses a recombinant AAV vector comprising a promoter that targets gene expression to myofibroblast-like lineage of cells in the heart. The present application, also discloses the preparation and use of AAV expression cassettes using a modified periostin promoter that successfully drives gene expression in cardiac myofibroblast-like cells. The present invention encompasses compositions and methods useful for treating myocardial infarction. Further comprising compositions and methods for preparing and using AAV vectors for targeting cells and inducing gene expression. The compositions and methods of the invention are useful for efficiently targeting cardiac myofibroblasts following a cardiac injury, disease, or disorder. Further comprising a kit for effecting alleviation of the various diseases or disorders recited herein.Type: GrantFiled: March 1, 2017Date of Patent: August 4, 2020Assignee: University of Virginia Patent FoundationInventor: Brent A. French
-
Patent number: 10724038Abstract: An in vitro method to discover or screen various an agent capable of modulating onset or progression of hepatic metastasis through inhibition or suppression of genes associated with prometastatic reaction in hepatic tissue. The method comprises preparing a primary mix-culture of hepatic parenchymal and non-parenchymal cells, exposing cells to colorectal cancer cells to induce a prometastatic reaction; the exposing the cells to the therapeutic agent to be screened, and then measuring gene expression profiles of cells exposed to the agent, and finally comparing the measured gene expression profile to a reference gene expression profile whereby to determine if the agent has a positive effect on inhibiting or suppressing metastatic reaction.Type: GrantFiled: December 7, 2018Date of Patent: July 28, 2020Assignee: Persona Biomed, Inc.Inventor: Fernando Vidal-Vanaclocha
-
Patent number: 10716814Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.Type: GrantFiled: November 30, 2018Date of Patent: July 21, 2020Assignee: Mesoblast International SàrlInventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
-
Patent number: 10717993Abstract: Described herein are methods of expressing nucleic acids in T cells pre-exposed to a co-stimulatory signal and then transduced with adenoviral vectors. In some embodiments, the co-stimulation is provided by anti-CD3 and anti-CD28 antibodies and the adenoviral vector is pseudotyped for T-cell entry. The invention also relates to compositions for carrying out these methods, provided as kits or pharmaceutical compositions that can be used to treat diseases including immunological conditions and hematological malignancies.Type: GrantFiled: April 11, 2016Date of Patent: July 21, 2020Assignee: Sangamo Therapeutics, Inc.Inventors: Michael C. Holmes, Gary Ka Leong Lee
-
Patent number: 10709739Abstract: A method of radiation-free hematopoietic stem cell (HSC) transplantation comprises administering to a mammalian subject one or two doses of 2 to 10 mg/kg body weight of a purine base analog, such as 6TG as a pre-conditioning step. The method further comprises engrafting into the subject hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient donor HSCs within 48 to 72 hours of the pre-conditioning step; and administering to the subject about 1 to 5 mg/kg of the purine base analog every two to four days for two to eight weeks following the engrafting step. The method is performed in the absence of pre-conditioning via radiation. The subject is therefore not treated with myeloablative radiation in preparation for transplantation, and thus the subject is free of myeloablative radiation-induced toxicity.Type: GrantFiled: February 1, 2019Date of Patent: July 14, 2020Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Noriyuki Kasahara, Robert H. Schiestl, Katrin Hacke, Akos Szakmary, Gay M. Crooks
-
Patent number: 10703794Abstract: An immunoresponsive cell, such as a T-cell expressing (i) a second generation chimeric antigen receptor comprising: (a) a signalling region; (b) a co-stimulatory signalling region; (c) a transmembrane domain; and (d) a binding element that specifically interacts with a first epitope on a target antigen; and (ii) a chimeric costimulatory receptor comprising (e) a co-stimulatory signalling region which is different to that of (b); (f) a transmembrane domain; and (g) a binding element that specifically interacts with a second epitope on a target antigen. This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.Type: GrantFiled: July 28, 2016Date of Patent: July 7, 2020Assignee: King's College LondonInventors: John Maher, Daniela Yordanova Achkova, Lynsey May Whilding, Benjamin Owen Draper
-
Patent number: 10696948Abstract: The present invention provides a method for preparing a clinically applicable, safe and less damaged cardiomyocyte population through a brief and simple procedure from a cell population obtained by induced differentiation of pluripotent stem cells into cardiomyocytes. The present invention relates to a method for preparing a cardiomyocyte population, the method comprising the steps of: (1) inducing pluripotent stem cells to differentiate into cardiomyocytes, (2) bringing a cell population obtained by the induced differentiation into contact with a laminin selected from the group consisting of laminin ?2?1?1, laminin ?2?2?1, laminin ?1?1?1 and laminin ?1?2?1, or a fragment thereof having integrin binding activity, and (3) retrieving cells adherent to the laminin or the laminin fragment.Type: GrantFiled: September 14, 2015Date of Patent: June 30, 2020Assignee: OSAKA UNIVERSITYInventors: Yukiko Ochi, Kiyotoshi Sekiguchi, Shigeru Miyagawa, Yoshiki Sawa, Antti Markus Siltanen
-
Patent number: 10696973Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.Type: GrantFiled: March 27, 2018Date of Patent: June 30, 2020Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Gang Chen, Changlin Dou, James P. Fandl
-
Patent number: 10689456Abstract: The invention provides a chimeric antigen receptor (CAR) having antigenic specificity for CD70, the CAR comprising: an antigen binding-transmembrane domain comprising a CD27 amino acid sequence lacking all or a portion of the CD27 intracellular T cell signaling domain; a 4-1BB intracellular T cell signaling domain; a CD3? intracellular T cell signaling domain; and optionally, a CD28 intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: GrantFiled: April 9, 2015Date of Patent: June 23, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Qiong J. Wang, Zhiya Yu, James C. Yang
-
Patent number: 10688136Abstract: Compositions and methods are provided for induction and maintenance of quiescence of stem cells.Type: GrantFiled: May 19, 2017Date of Patent: June 23, 2020Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Marco Quarta, Thomas A. Rando
-
Patent number: 10689431Abstract: Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.Type: GrantFiled: September 18, 2018Date of Patent: June 23, 2020Assignee: LENTIGEN TECHNOLOGY, INC.Inventors: Rimas J. Orentas, Dina Schneider, Waleed M. Haso, Stefan Miltenyi, Boro Dropulic
-
Patent number: 10676717Abstract: Chimeric transmembrane immunoreceptors (CAR) which include an extracellular domain that includes IL-13 or a variant thereof that binds interleukin-13R?2 (IL13R?2), a transmembrane region, a costimulatory domain and an intracellular signaling domain are described.Type: GrantFiled: March 12, 2018Date of Patent: June 9, 2020Assignee: City of HopeInventors: Christine E. Brown, Stephen J. Forman
-
Patent number: 10668101Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.Type: GrantFiled: December 23, 2013Date of Patent: June 2, 2020Assignee: MESOBLAST INTERNATIONAL SÁRLInventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
-
Patent number: 10670582Abstract: Described are methods and compositions for increasing islet-1 (Isl1) activity (e.g., biological activity) and or expression (e.g., transcription and/or translation) in a biological cell and or in a subject.Type: GrantFiled: September 14, 2015Date of Patent: June 2, 2020Assignee: Massachusetts Eye and Ear InfirmaryInventors: Mingqian Huang, Albena Kantardzhieva, Zheng-Yi Chen
-
Patent number: 10669596Abstract: The present disclosure provides methods for inducing cell cycle reentry of postmitotic cell. The present disclosure further provides cells and compositions for treating diseases, such as cardiovascular diseases, neural disorders, hearing loss, and diabetes.Type: GrantFiled: April 5, 2016Date of Patent: June 2, 2020Assignee: The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David GladstoneInventors: Tamer M. A. Mohamed, Deepak Srivastava
-
Patent number: 10669547Abstract: The invention provides compositions and methods of making and using effector oligonucleotides, including effector oligonucleotides with greater than one mismatch as compared to its target sequence. These effector oligonucleotides are useful for improving the efficiency of genomic editing as well as providing therapeutic benefits to individuals in need thereof.Type: GrantFiled: March 13, 2014Date of Patent: June 2, 2020Inventor: Kambiz Shekdar
-
Patent number: 10660917Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.Type: GrantFiled: May 23, 2017Date of Patent: May 26, 2020Assignee: Maxcyte, Inc.Inventors: Linhong Li, Madhusudan V. Peshwa
-
Patent number: 10654907Abstract: Provided is a method for determining a TCR polypeptide chain that can form a TCR specific for a peptide of interest. Also provided are methods and compositions for producing a cell expressing a T cell receptor (TCR) specific for a peptide of interest, methods and compositions for producing a TCR chain nucleic acid and/or pair of TCR chain polypeptides and/or nucleic acids encoding a TCR, a cell population comprising the cell harboring the nucleic acids encoding a TCR obtained by said method, and a method for treating a disorder comprising administering to the subject said cell population.Type: GrantFiled: January 28, 2015Date of Patent: May 19, 2020Assignee: University Health NetworkInventors: Naoto Hirano, Munehide Nakatsugawa, Toshiki Ochi
-
Patent number: 10647999Abstract: The present invention relates to nucleic acid molecules which are capable of promoting transcription of operably-linked heterologous polynucleotides in mammalian cells. The invention also relates to expression vectors and host cells which comprise the nucleic acid molecules of the invention. Such expression vectors may be used to produce recombinant proteins, e.g. antibodies and lentiviral polypeptides.Type: GrantFiled: February 28, 2017Date of Patent: May 12, 2020Assignee: Oxford Genetics LimitedInventors: Ryan Cawood, Richard Parker-Manuel, Weiheng Su
-
Patent number: 10640771Abstract: Compositions and methods for treating macular degeneration are disclosed. The methods utilize IL17 inhibitors, such as IL17 receptors, as well as fusion proteins including an IL17 receptor fused with a multimerization domain, and recombinant viral vectors encoding such fusions.Type: GrantFiled: April 17, 2014Date of Patent: May 5, 2020Assignees: GENZYME CORPORATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY THEInventors: Samuel Wadsworth, Abraham Scaria, Chi-Chao Chan
-
Patent number: 10632212Abstract: The invention provides improved compositions and methods for achieving gene therapy in hematopoietic cells and hematopoietic precursor cells, including erythrocytes, erythroid progenitors, and embryonic stem cells. The invention further provides improved gene therapy methods for treating hematopoietic-related disorders. Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.Type: GrantFiled: September 13, 2018Date of Patent: April 28, 2020Assignees: bluebird bio, Inc., Massachusetts Institute of TechnologyInventors: Philippe Louis Leboulch, Robert Pawliuk, Karen Westerman